Artificial intelligence-based prognostic models in acute myeloid leukemia: systematic review and meta-analysis
AI-based prognostic tools for acute myeloid leukemia now match or exceed standard clinical assessments, offering doctors a powerful new decision-support option.
This systematic review and meta-analysis comprehensively evaluates artificial intelligence prognostic models in acute myeloid leukemia and quantifies their accuracy compared to standard clinical tools. The study provides the highest-level evidence to date supporting integration of AI prognostics into AML clinical workflow.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- AML patients across published AI prognostic model studies
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Blood Neoplasia
Why it surfaced
Highest-quality evidence design (SR/MA) for AI prognostics in AML; directly relevant to CBC/ML hematology watchlist; breaks 14-day consecutive drought on that topic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.